T1	Participants 56 128	metastatic and/or unresectable malignant gastrointestinal stromal tumors
T2	Participants 351 455	patients with CD117(+) unresectable and/or metastatic malignant gastrointestinal stromal tumors (GISTs).
T3	Participants 606 639	patients with progressive disease
T4	Participants 793 918	European Organization for Research and Treatment of Cancer (n = 946) and the other by the Southwest Oncology Group (n = 746).